Protocol to Assess the Severity of Acute Kidney Injury
Launched by GEORGE WASHINGTON UNIVERSITY · May 5, 2008
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.
Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years and older
- • Increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater or equal to 150 to 200% from baseline or sustained oliguria(mean urine output of \<0.5 cc/kg/hr for 6 hours within 48 hours)
- • Written informed consent
- • Patients who already have a indwelling bladder catheter
- Exclusion Criteria:
- • Voluntary refusal or missing written consent of the patient or the designated legal representative
- • Patients with advanced Chronic Kidney Disease - as defined by a baseline GFR of \< 30 ml/min as calculated by the MDRD equation
- • Patients with renal transplantation
- • Pregnancy
- • Patients with an allergy or sensitivity to loop diuretics
- • Patients with a clinical syndrome consistent with pre-renal AKI
- • Defined by fractional excretion of Na of \< 1% AND no evidence of the urinary casts, or
- • Patients that are under-resuscitated as deemed by treating clinical team or
- • Patients who are actively bleeding
- • Patients with a clinical syndrome of post-renal AKI
- • Any radiological study that shows hydro-ureter, or
- • Clinical scenario wherein the obstruction is considered a likely possibility of the cause of AKI
About George Washington University
George Washington University (GWU) is a leading academic institution dedicated to advancing medical research and education. As a clinical trial sponsor, GWU leverages its extensive resources and expertise to facilitate innovative studies that aim to improve healthcare outcomes. The university's commitment to ethical research practices, collaboration with multidisciplinary teams, and engagement with diverse populations underscores its role in addressing critical health challenges. By fostering a rigorous scientific environment, GWU strives to translate research findings into effective clinical applications, ultimately enhancing patient care and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Lakmir S Chawla, MD
Principal Investigator
George Washigton University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials